Member Info for Moneymunch

More good news expected soon to drive the sp North again, the very reason for the impressive rise witnessed over the last number of months, with Genflow reporting compelling data on the Dog Trial, and progress made on the rest of the pipeline, Glaucoma, Mash and Sarcopenia, not to mention the highly significant strategic collaboration with Acuitas Therapeutics, globally recognised leader in lipid nanoparticle ("LNP") delivery systems whose technology has underpinned some of the most commercially successful mRNA therapeutic programmes brought to market to date, fully funded by Acuitas- speaks volumes, as well as confirmation of multiple Tier 1 Animal Healthcare companies under Confidential Disclosure Agreements on the Dog Study....Amazing transformational potential and prospects. Gl ;-)

Ps and Genflow have an extra £1.5m cash in the bank since March, £800k share subscription, €330k 1st tranche from the €4m non-dilutive grant money and £450k cash from the warrants exercised, news of which initially spooked a few pi's, which has caused this temporary drop in sp....all bodes well and multiple potential near term newsflow to take the sp to new highs and beyond. Exciting times for those invested!!! ;-)

In the meantime, it would appear there are a few about, intent to discourage and deter....they want your shares!!! Gla :-)

Ps Genflow's cash position, with more grant money expected soon, undoubtedly strengthens their hand and provides plenty of leverage in any commercial deal negotiations with Major Pharma . Gla :-)

Yes indeed Molotovkid, and Genflow have an extra £1.5m cash in the bank since March, £800k share subscription, €330k 1st tranche from the €4m non-dilutive grant money and £450k cash from the warrants exercised, news of which initially spooked a few pi's, which has caused this temporary drop in sp....all bodes well and multiple potential near term newsflow to take the sp to new highs and beyond, regardless of who posts and who doesn't!!! Gl :-)

Every chance Perseverance, the Dog Study is expected to be completed by end of July, but "additional analysis, including methylation clock (biological age) assessment and muscle histology", could drop at anytime and positive data , especially confirming rejuvenation, will be highly significant to proceedings and potentially company defining, and trigger an early move by one of the multiple Tier 1 Animal Healthcare companies under Confidential Disclosure Agreements. Exciting times. Gl :-)

8th April 2026

The SLAB study remains ongoing, with all dogs continuing to be actively monitored and evaluated. The trial is expected to continue for a further four months, with completion anticipated at the end of July 2026. Additional analyses, including methylation clock (biological age) assessment and muscle histology, are in progress and are expected to provide further mechanistic and quantitative insight into the therapy's impact.

Dr Eric Leire, Chief Executive Officer of Genflow said: "These follow-up observations are important as they extend our understanding beyond initial efficacy and into persistence of effect. The consistency of improvements across multiple functional endpoints, together with the continued absence of safety concerns, strengthens our confidence that SIRT6 gene therapy is delivering a sustained biological impact.

Based on the data observed to date, we believe this supports the positioning of our SIRT6 platform as a potentially disease-modifying approach to addressing age-related decline in companion animals. As the study progresses, we continue to engage with prospective partners across animal health to explore licensing, co-development, and commercialisation opportunities."

Further updates will be provided as additional data becomes available.

Fingers crossed for evidence of rejuvenation from the eagerly awaited Methylation Clock and Muscle Histology Data from the Dog Study. A potential game-changing defining moment for all concerned. Gla :-)

An excellent audio article on the compelling potential, including rejuvenation, of Sirt6. Gla ;-)

Can aging be reversed? Israeli scientists uncover major longevity breakthrough

A new Bar-Ilan University study suggests some age-related changes in liver cells may be reversible after researchers boosted the longevity-linked protein SIRT6, restoring aging mouse livers to patterns resembling younger ones.

One of the major questions occupying aging researchers is whether aging is a one-way process, or whether some of the cellular changes that occur over the years can still be reversed. In recent years, scientists have increasingly come to understand that aging is not merely the body’s gradual wear and tear, but also a profound change in the way cells read and activate their genetic material.

Can aging be reversed? Israeli scientists uncover major longevity breakthrough htTps://share.google/chZgjYGLLd9YVp8Al

The price moved up on Friday. Gl :-)

Angel Versetti in . 3rd+

+ Follow

Longevity Venture Builder / Owner ... Visit my website 4mo.

The confluence of the market trends, technology maturity and political shifts makes longevity the prime industry poised to grow exponentially over the next few years. Proud to share our Family Office's insights on the investment thesis of Longevity for 2026.

Read more here:

https://lnkd.in/gHdmmZmb

Longevity: Versetti Family Office's Bold Investments htTps://share.google/kf0RgCwPe1FRGKBjM

Genflow Biosciences is a company focused on longevity and has secured European patent rights for a SIRT6 variant, according to a LinkedIn post from Versetti Family Office.

Versetti Family Office posted about Genflow Biosciences' patent progress, but this doesn't confirm a direct investment; it could be a statement of interest or awareness within the longevity sector.

.....

Longevity: Versetti Family Office's Bold Investments

PRESS RELEASE

Published September 20, 2025

.......

Angel believes that even if lifespan extension is beyond our current scientific possibilities, we could at the very least solve lifespan: "The very least longevity could do is to enable people to reach old age not unlike the society in Brave New World, even if people cannot live longer, at least they can die fit and beautiful, not in misery and slow decay; after all, the biggest argument of the general population against longevity is that they would not want to extend the miserable old years of their lives - let's focus on that, while we seek answers to how to expand lifespan!"

A Future-Oriented Vision

What sets Angel Versetti and Versetti Family Office apart is not only a remarkable track record as biotech and AI investors, but a sense of possibility and "moonshot" thinking at the heart of every venture. Angel himself is a serial entrepreneur having exited multiple successful startups in AI and Web3 domain. He brings his entrepreneurial skillset and passion, as well as that of many of his prior ventures' early employees to his investments. Versetti Family Office maintains an open call to founders working on longevity and AI: bring your boldest ideas and let's shape the future together. Versetti Family Office has earmarked 50 million USD to invest in the boldest commercially viable longevity moonshots.

Leadership & Global Recognition

Angel Versetti's expertise is respected by leaders and policymakers around the world. In summer 2025, he was invited to speak at the UK Parliament as a Roundtable speaker, sharing his insights on innovation, longevity, and the future of healthtech with government officials and top industry figures. This autumn, he will address the Longevity Summit in China and has recently spoken at the AIM Summit in the UAE alongside the former Prime Minister of the UK Boris Johnson and the Minister of Economy of the UAE. These high-profile engagements signal how Angel's opinions are valued across continents by the world's leading governments and experts in longevity and deeptech. He believes governments, especially in most developed and advanced countries have imperative to assure healthy lifespan of their citizens: "Imagine the economic value for the country, if wise and seasoned 100-year old's had the youthfulness, sharpness of mind and energy of 30 year olds - how much the society would benefit; how much stress would be taken from the hospitals and social security networks".

Longevity: Versetti Family Office's Bold Investm

While family offices cannot legally hide shareholdings in London Stock Exchange (LSE) listed companies above regulatory thresholds, they can sometimes obscure beneficial ownership through complex structures, nominee shareholders, or by staying below mandatory disclosure percentages. UK rules, including Persons with Significant Control (PSC) requirements and DTR 5 disclosure rules, mandate disclosure, but offshore vehicles or trusts can create layers that complicate transparency.

LSEG

+4

Key ways ownership is sometimes obscured, and the limitations:

Nominee Shareholders: Shares may be registered in the name of a bank, broker, or custodian (nominee) rather than the family office directly, masking the true owner on public registers.

Threshold Management: Disclosure is generally required when voting rights reach or exceed 3% (or 5% for some AIM companies). Family offices may split holdings across multiple entities to keep each below these thresholds.

Offshore Structures: Using companies or trusts in jurisdictions with strict secrecy laws, such as Cayman or Bermuda, can hide the ultimate beneficial owner.

Trusts and Corporate Entities: Placing shares inside complex trust structures separates legal ownership from beneficial control, making it challenging to identify the ultimate beneficiary.

Not sure if any shares/warrants have been passed on, and reckon they're still in the tight hands of the Major shareholders who've exercised them, and presumbly plenty of time before a TR1 is required, and highly likely the reason they were exercised at this time was to provide Genflow with additional/urgent funding to advance/progress one of their programmes??? No doubt all will be revealed in the coming days, although shares held by family offices and the like, no doubt can be hidden??? Gl:-)

Any investor holding 3% or more of a company’s voting rights is required to publicly disclose their identity, as mandated by the FCA’s Disclosure Guidance and Transparency Rules (DTRs).

Ah yes of course Alwaysraining, my Ai post refers to private and not listed Lse main market, although we've had quite a few share subscriptions over the last year or so, with little clarity of where they've gone. The 28m plus warrants from May 2025, relate to the 62,500 000m shares that were subscribed to Eric and then passed on a purchaser via an institution. We had a TR1 a couple of days later from Dr. Moayyed Al-Qurtas, the Saudi billionaire, confirming a 4.5% holding, which equated to around 20m shares, but no notice on where the other 40m went???? Gl :-)

Major shareholders on the London Stock Exchange (LSE) Main Market generally cannot remain anonymous due to mandatory transparency rules. Any investor holding

or more of a company’s voting rights is required to publicly disclose their identity, as mandated by the FCA’s Disclosure Guidance and Transparency Rules (DTRs).

London Stock Exchange

+2

Key Disclosure Requirements:

Threshold Disclosures: Once an investor crosses the

threshold, and every

thereafter, they must notify the company and the market.

Transparency Directive: Main Market companies are subject to strict ongoing disclosure requirements that require identifying controlling parties.

No Hiding in Nominees: While nominees can hold shares, the underlying owner must disclose their interest once thresholds are met, as the FCA monitors compliance with these disclosure rules.

Exceptions: While a "shadow" director who does not take a formal management role might escape some specific related-party transaction disclosures, they still generally fall under the broader disclosure requirements for significant ownership.

ECGI

+4

For investors requiring privacy, the Main Market is generally not suited for holding 3% or more of voting shares.

Ps a major shareholder, holding less than 25% can remain anonymous to the public, apparently. Gl :-)

a shareholder holding less than 25% of shares or voting rights in a UK company can generally remain anonymous on public registers.

OSINT.UK

Here are the key details regarding anonymity for sub-25% holders:

PSC Register Threshold: The legal requirement to disclose identity on the Persons of Significant Control (PSC) register at Companies House generally applies to individuals holding more than 25% of shares or voting rights, or exercising significant control.

Sub-25% Privacy: Shareholders with 25% or less are not required to appear on the public PSC register. While their names appear in the company's private internal records (register of members), they are not part of the publicly accessible profile.

The "Control" Exception: Even if a shareholder holds under 25%, they may still be deemed a PSC if they exercise "significant influence or control" over the company. In such cases, they must be registered.

Nominee Shareholders: Nominee arrangements are sometimes used, but if the beneficial owner holds more than 25%, they must still be declared. If the beneficial owner holds 25% or less, the nominee's name is typically visible, adding a layer of separation, though this is not a legal way to hide a true controlling party.

Inform Direct

+5

Disclaimer: These rules relate specifically to UK company transparency requirements as of early 2026.

Wednesday, not yesterday.

They confirmed in the RNS they expected the shares to be admitted yesterday, and so they're not going to waste money to issue another RNS ( it costs a few quid ) to reaffirm , and as far as the TR1's are concerned, we'll just have to wait and see, in the meantime, fingers crossed for a run of very positive news from now on in. Gl :-)

Cash is already in Genflow's coffers. Gl :-)

2,631,578 new ordinary shares being issued pursuant to the exercise of warrants granted and announced on 5 March 2026.

Subscription monies of £49,999.99 have been received by the Company in respect of the full exercise of these warrants.

28,124,999 new ordinary shares being issued pursuant to the exercise of warrants granted and announced on 8 May 2025.

Subscription monies of £309,375 have been received by the Company in respect of this exercise.

Hopefully news on Monday Porter, or certainly sometime this coming week with any luck. Gl :-)